MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients

Blood

Volumn 111, Issue 4, 2008, Pages 1855-1861

  Wandt, Hannes ^a   Schäkel, Ulrike ^b   Kroschinsky, Frank ^b   Prange Krex, Gabriele ^b   Mohr, Brigitte ^b   Thiede, Christian ^b   Pascheberg, Ulrich ^c   Soucek, Silke ^b   Schaich, Markus ^b   Ehninger, Gerhard ^b  

^a KLINIKUM NÜRNBERG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Zytogenetisches Labor Dr Eberhard u Partner   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CLINICAL TRIAL; CYTOGENETICS; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; DYSPLASIA; FEMALE; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTILINEAGE DYSPLASIA; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 41349105936     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-101162     Document Type: Article

References (43)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Cooperative Group. Br J Haematol. 1976;33:451-458.
2. Bennet JM, Catovsky D, Daniel MT, et al. Proposal for the classification of myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
3. Bett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American- British Cooperative Group. Ann Intern Med. 1985;103:620-625.
4. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med. 1985;103:460-462.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol. 1991;78:325-329.
6. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol. 1987;66:445-450.
7. Goasguen JE, Matsuo T, Cox C, et al. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6:520-525.
8. Kahl C, Florschütz A, Müller G, et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol. 1997;75:91-94.
9. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-951.
10. Estienne MH, Fenaux P, Preudhomme C, et al. Prognostic value of dysmyelopoietic features in de novo acute myeloid leukemia: a report on 132 patients. Clin Lab Haematol. 1990;12:57-65.
11. Jinnai I, Tomonaga M, Kuriyama K, et al. Dysmegakaryocytopoiesis in acute leukemias: its predominance in myelomonocytic (M4) leukaemia and implication for response to chemotherapy. Br J Haematol. 1987;66:467-472.
12. Kuriyama K, Tomonaga M, Matsuo T, et al. Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol. 1994;86:767-773.
13. Kuriyama K, Tomonaga M, Kobayashi T, et al. Morphological diagnoses of the Japan Adult Leukemia Study Group acute myeloid leukemia protocols: Central Review. Int J Hematol. 2001;73:93-99.
14. Arber DA, Stein AS, Carter NH, et al. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol. 2003;119:672-680.
15. Ballen KK, Gilliland DG, Kalish LA, et al. Bone marrow dyplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival. Cancer. 1994;73:314-321.
16. Haferlach T, Schoch C, Löffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21:256-265.
17. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia. Br J Haematol. 2003;120(1):56-62.
18. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
19. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukemia. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organisation of Tumours, Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;2001: 75-108.
20. Vardiman JW, Harris NL, Brunning RD, et al. Prerequisites for the diagnosis of myeloid neoplasms by the WHO classification. Blood. 2002;100:2292-2302.
21. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
22. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
23. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
24. Bloomfield CD, Lawrence D, Byrd JK, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
25. Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B Study 8461. J Clin Oncol. 2004;22:2410-2418.
26. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
27. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266.
28. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-4020.
29. Mrózek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-448.
30. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group. Blood. 1999;94:1192-1200.
31. Schaich M, Ritter M, Illmer T, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol. 2001;112:300-307.
32. Shaffer LG, Tommerup N, eds. ISCN 2005, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger; 2005.
33. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
34. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.
35. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
36. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1989;89:3323-3329.
37. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-73.
38. Hann M, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medial Research Council's 10th AML Trial (MRC AML10). Blood. 89:2311-2318.
39. Kolitz JE, George SL, Doge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of cancer and leukemia Group B Study 9621. J Clin Oncol. 2004;22:4290-4301.
40. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
41. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995;85:2643-2653.
42. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087-1094.
43. Haferlach T, Kohlmann A, Schnittger S, et al. Diagnosis of leukemia by gene expression profiling. Blood. 2005;106:1189-1198.